New York, United States , Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Global GI Stool Testing Market Size is Expected to Grow from USD 580.0 Million in 2023 to USD 1195 ...

Multitarget stool DNA testing identified 60 of 65 participants with cancer, including 56 of the 60 participants with screening-relevant cancers, for respective sensitivities of 92.3% (95% confidence ...

Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term ...

A large real-world study found that fewer than half of adults who started colorectal cancer (CRC) screening with an at-home stool test completed the recommended repeat test, creating gaps in ...

Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...

(MENAFN- GlobeNewsWire - Nasdaq) The Global GI Stool Testing Market Size was Valued at USD 580.0 Million in 2023 and the Worldwide GI Stool Testing Market Size is Expected to Reach USD 1195 Million by ...

Conclusions In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded ...

ORLANDO -- Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool sample collections, according to a survey study. Among survey ...